Nektar Therapeutics (NKTR) Restructuring Costs (2022 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Restructuring Costs of $796000.0 for Q1 2026, up 371.01% year-over-year from $169000.0 in Q1 2025, and down 90.72% quarter-over-quarter from $8.6 million in Q4 2025.
Nektar Therapeutics (NKTR) Restructuring Costs (2022 - 2026) Analysis & Trends
Nektar Therapeutics' Restructuring Costs history runs 5 years deep, the most recent figure standing at $796000.0 for Q1 2026.
- In Q1 2026, Restructuring Costs rose 371.01% year-over-year to $796000.0; the TTM figure through Mar 2026 stood at $10.0 million (down 33.01% YoY), while the FY2025 annual figure was $9.3 million, down 40.45% from the prior year.
- Restructuring Costs for Q1 2026 stood at $796000.0, down from $8.6 million in the prior quarter.
- The five-year high for Restructuring Costs was $106.0 million in Q2 2022, with the low at -$41.2 million in Q4 2023.
- The 5-year median for Restructuring Costs is $1.4 million (2023), against an average of $7.3 million.
- The sharpest annual moves came in 2023 and 2024: Restructuring Costs tumbled 455.85% in 2023, then surged 880.01% in 2024.
- Nektar Therapeutics' Restructuring Costs stood at $11.6 million in 2022, then sank by 455.85% to -$41.2 million in 2023, then surged by 103.3% to $1.4 million in 2024, then jumped by 530.51% to $8.6 million in 2025, then slumped by 90.72% to $796000.0 in 2026.
- Business Quant data shows NKTR's Restructuring Costs at $796000.0 in Q1 2026, $8.6 million in Q4 2025, and $140000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 796,000.00 |
| Dec 31, 2025 | 8.58 Mn |
| Sep 30, 2025 | 140,000.00 |
| Jun 30, 2025 | 447,000.00 |
| Mar 31, 2025 | 169,000.00 |
| Dec 31, 2024 | 1.36 Mn |
| Sep 30, 2024 | 46,000.00 |
| Jun 30, 2024 | 13.29 Mn |
| Mar 31, 2024 | 975,000.00 |
| Dec 31, 2023 | -41.21 Mn |
| Sep 30, 2023 | 535,000.00 |
| Jun 30, 2023 | 1.36 Mn |
| Mar 31, 2023 | 1.60 Mn |
| Dec 31, 2022 | 11.58 Mn |
| Sep 30, 2022 | 16.83 Mn |
| Jun 30, 2022 | 106.05 Mn |
| Mar 31, 2022 | 1.48 Mn |